282 related articles for article (PubMed ID: 32129102)
1. Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis.
Rossini M; Epis OM; Tinazzi I; Grembiale RD; Iagnocco A
Expert Opin Biol Ther; 2020 Jul; 20(7):787-798. PubMed ID: 32129102
[TBL] [Abstract][Full Text] [Related]
2. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
Yeremenko N; Paramarta JE; Baeten D
Curr Opin Rheumatol; 2014 Jul; 26(4):361-70. PubMed ID: 24827753
[TBL] [Abstract][Full Text] [Related]
3. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
5. Enthesitis in psoriatic arthritis (Part 1): pathophysiology.
Araujo EG; Schett G
Rheumatology (Oxford); 2020 Mar; 59(Suppl 1):i10-i14. PubMed ID: 32159793
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
Ceribelli A; Motta F; Vecellio M; Isailovic N; Ciccia F; Selmi C
Front Immunol; 2021; 12():622770. PubMed ID: 34149686
[TBL] [Abstract][Full Text] [Related]
7. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
Zabotti A; Goletti D; Lubrano E; Cantini F
Expert Opin Drug Saf; 2020 Jan; 19(1):69-82. PubMed ID: 31847608
[No Abstract] [Full Text] [Related]
8. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
9. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
Nagayasu A; Nawata M; Saito K; Tanaka Y
Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
[TBL] [Abstract][Full Text] [Related]
10. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
11. Biological and synthetic target DMARDs in psoriatic arthritis.
Silvagni E; Bortoluzzi A; Ciancio G; Govoni M
Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178
[TBL] [Abstract][Full Text] [Related]
12. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
Rosine N; Miceli-Richard C
Front Immunol; 2020; 11():553742. PubMed ID: 33488572
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.
Nguyen CT; Bloch Y; Składanowska K; Savvides SN; Adamopoulos IE
Clin Immunol; 2019 Sep; 206():15-22. PubMed ID: 30196070
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.
Felice C; Pugliese D; Papparella LG; Pizzolante F; Onori E; Gasbarrini A; Rapaccini GL; Guidi L; Armuzzi A
Expert Rev Clin Immunol; 2018 Sep; 14(9):751-759. PubMed ID: 30118354
[TBL] [Abstract][Full Text] [Related]
15. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
17. Effect of enthesitis on 1505 Brazilian patients with spondyloarthritis.
Carneiro S; Bortoluzzo A; Gonçalves C; Silva JA; Ximenes AC; Bértolo M; Ribeiro SL; Keiserman M; Skare T; Menin R; Azevedo V; Vieira W; Albuquerque E; Bianchi W; Bonfiglioli R; Campanholo C; Carvalho HM; Costa Id; Duarte A; Kohem C; Leite N; Lima SA; Meirelles ES; Pereira IA; Pinheiro MM; Polito E; Resende GG; Rocha FA; Santiago MB; Sauma Mde F; Valim V; Sampaio-Barros PD
J Rheumatol; 2013 Oct; 40(10):1719-25. PubMed ID: 23858049
[TBL] [Abstract][Full Text] [Related]
18. Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative.
Balint PV; Terslev L; Aegerter P; Bruyn GAW; Chary-Valckenaere I; Gandjbakhch F; Iagnocco A; Jousse-Joulin S; Möller I; Naredo E; Schmidt WA; Wakefield RJ; D'Agostino MA;
Ann Rheum Dis; 2018 Dec; 77(12):1730-1735. PubMed ID: 30076154
[TBL] [Abstract][Full Text] [Related]
19. Targeting the interleukin-23/17 axis in axial spondyloarthritis.
Paine A; Ritchlin CT
Curr Opin Rheumatol; 2016 Jul; 28(4):359-67. PubMed ID: 27152702
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Manasson J; Wallach DS; Guggino G; Stapylton M; Badri MH; Solomon G; Reddy SM; Coras R; Aksenov AA; Jones DR; Girija PV; Neimann AL; Heguy A; Segal LN; Dorrestein PC; Bonneau R; Guma M; Ciccia F; Ubeda C; Clemente JC; Scher JU
Arthritis Rheumatol; 2020 Apr; 72(4):645-657. PubMed ID: 31729183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
